Description
This product is a recombinant humanized antibody against ERBB2 (also known as HER2) for cancer treatment. The antibody specifically binds the extracellular domain of ERBB2 and binds to cell surface-associated ERBB2 with an affinity comparable to that of Trastuzumab, but binds to a different epitope. The antibody was expressed in mammalian cells with chemically defined culture media and was purified by affinity chromatography.
Target
ERBB2
Target Alias Names
Erb-B2 Receptor Tyrosine Kinase 2, V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2, Tyrosine Kinase-Type Cell Surface Receptor HER2, Neuro/Glioblastoma Derived Oncogene Homolog, Human Epidermal Growth Factor Receptor 2, Metastatic Lymph Node Gene 19 Protein, Proto-Oncogene C-ErbB-2, Proto-Oncogene Neu, EC 2.7.10.1, P185erbB2, MLN 19, HER2, NGL, NEU, V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (Neuro/Glioblastoma Derived Oncogene Homolog)
Isotype/Mimetic
Humanized IgG
Animal-Derived Biomaterials Used
None
Sequence Available
No
Original Discovery Method
Human-derived phage display
Original Discovery Information Provided On Datasheet
No
Antibody/Binder Origins
Animal-free discovery, In vitro recombinant expression